

InnoCentive and Collaborative Drug Discovery Partner to offer InnoCentive Solvers Free Access to CDD's Software

Partnership provides InnoCentive Solvers with software needed to analyze and develop more effective solutions to scientific Challenges


Waltham, Mass. October 01, 2008 – [InnoCentive, Inc.](#), the global innovation marketplace, and [Collaborative Drug Discovery, Inc.](#) (CDD) today announced that they have partnered to offer InnoCentive Solvers access to web-based software to aid in solving scientific Challenges. Under the partnership, InnoCentive will offer links to CDD's site from specific scientific Challenges and InnoCentive Solvers will have the opportunity to collaborate on Challenges with CDD's users.

CDD's software allows scientists to organize complex research data and collaborate within multiple research groups world-wide. CDD's software is used by academics, start-ups, Contract Research Organizations (CROs), large corporations focused on BioPharma and non-profit organizations.

News Highlights


- The partnership gives InnoCentive Solvers the opportunity to experiment with CDD's software and utilize its benefits in order to develop faster and more effective solutions to InnoCentive Challenges.
- It is also exclusive to InnoCentive Solvers and provides them with a platform to interact and collaborate with other scientists who use CDD's software and get feedback and advice for solving certain Challenges.
- CDD's software helps scientists to capture and organize fragmented data and keep pace with high-throughput experiments so data sets don't pile up unanalyzed. It also helps to avoid redundancies, maintain project continuity, and control data.
- Solvers who use CDD have the option of keeping their work private or sharing it openly with the scientific community.
- CDD helps research groups to safely store and intelligently analyze their research data. Typical data includes small molecule, enzyme, cell and animal bioactivity data accumulated from both low-throughput and high-throughput screens.


Figure 1. Screenshot of InnoCentive Challenge with CDD Software Link.



Heat-Stable, Shelf-Stable Food Foam

Challenge Reward: **\$50,000 USD** Challenge Type: **RTP** INNOCENTIVE 6528808

 Collaborative Drug Discovery

 The Seeker, a Fortune 500 company, is looking for ingredients or technology to produce heat-stable, shelf-stable food foam. More details are available once you register as an InnoCentive Solver. [Read More](#)




 **DEADLINE: Oct 14, 2008**  **347 Project Rooms**  **Challenge Posted: Jul 14, 2008**

Figure 2. Sample Screenshot of CDD's intuitive web-based user interface.

The screenshot displays the CDD (Collaborative Drug Discovery) web interface. At the top, the logo and 'Barry Bunin's Site' are visible, along with user navigation links like 'Welcome, Barry: Account Preferences | Logout'. The main navigation bar includes 'Archive', 'Mine', and 'Collaborate' buttons. Below this, a status bar indicates 'Currently viewing my group's data only' and provides links for 'New Query' and 'Saved Queries'. The central area is titled 'Mine Protocols and Molecules' and features a search filter section. This section includes dropdown menus for 'Protocols' (set to 'CCK-A Dose Response Curve') and 'with readout' (set to 'IC50' with a '<' operator and a value of '10 (uM)'). A second filter is set to 'Cytotoxicity'. Below the filters, there is a 'Chemical properties' section with input fields for Molecular weight, log P, H-bond donors, H-bond acceptors, pKa, Exact mass, Atom count, and Polar surface area. On the right, a 'MarinView' window displays a 3D ball-and-stick model of a complex organic molecule with multiple nitrogen and oxygen atoms. A small chemical structure is also visible in the bottom left of the main interface.

Executive Quotes

Barry Bunin, CEO and President, Collaborative Drug Discovery, Inc.

"This partnership brings together two companies that are focused on open innovation and collaboration and see these two ideas as the foundation of innovation in the future. By offering our solution to InnoCentive's active community, we are giving InnoCentive Solvers the resources they need to develop cost effective, efficient solutions that will benefit Seekers."

Dwayne Spradlin, CEO of InnoCentive, Inc.

"We are always looking for ways to support our Solvers so that they have the tools they need to solve the Challenges our Seekers post. This partnership allows us to do this and gives our Solvers access to CDD's intuitive software which helps saves time and energy and ensures more efficient solutions to research problems."

About Collaborative Drug Discovery, Inc.

Collaborative Drug Discovery, Inc. (CDD) - <http://www.collaborativedrug.com> - provides web-based software that organizes research data to help scientists advance new drug candidates more effectively. The CDD database enables scientists to "archive, mine, and collaborate"® around chemical and biological drug discovery data through a web-based interface. The software helps distributed research groups to safely store and intelligently analyze small molecule, enzyme, cell and animal bioactivity data accumulated from both low-throughput and high-throughput screens. Unique collaboration features and CDD's community-oriented approach help unite globally dispersed humanitarian efforts against neglected infectious diseases. Similar collaborative strategies are also rapidly gaining prominence in the commercial arena. CDD offers its industrial-strength database software at a price affordable to academic laboratories, research foundations, and small companies.

About InnoCentive

Founded in 2001, InnoCentive built the first global web community for open innovation, enabling scientists, engineers, professionals and entrepreneurs to collaborate to deliver breakthrough solutions for R&D-driven organizations. InnoCentive Seekers, who collectively spend billions of dollars on R&D, submit complex problems to the InnoCentive Marketplace where more than 155,000 engineers, scientists, inventors, business people, and research organizations in more than 175 countries are invited to solve them. Solvers who deliver the most innovative solutions receive financial awards ranging up to US\$1,000,000.

InnoCentive's Seekers include commercial, government and non-profit organizations such as Procter & Gamble, Pendulum, Eli Lilly and Company, Janssen, Solvay, GlobalGiving and The Rockefeller Foundation.

For more information on InnoCentive, go to: www.innocentive.com.

InnoCentive and InnoCentive Challenge are registered trademarks of InnoCentive, Inc. Other product or service names mentioned herein are the trademarks of their respective owners.

For More Information contact:

Connie French
Enterprise Marketing Manger
978-482-3300
press@innocentive.com

Barry Bunin, PhD
Collaborative Drug Discovery (CDD) President
650-204-3084
info@collaborativedrug.com